Deine Themen. Neue Beiträge.

Eine kompakte Browser-Benachrichtigung, wenn es Neues gibt. Höchstens einmal am Tag – auch ohne Konto.

Was interessiert dich?

Freiwillig und jederzeit hier abschaltbar. Themenauswahl und Geräte-Abonnement werden gespeichert; eine E-Mail-Adresse ist nicht nötig. Datenschutz

Den Harbor durchsuchenEN/DEKonto
Mediathek· Matt KaeberleinAudio: Englisch (Vereinigte Staaten)

Can Rapamycin Reverse Alzheimer's? What the Data Actually Shows

Vorschaubild von YouTube. Abspielen lädt den YouTube-Player.

Verlauf & EmpfehlungenAus

Zuletzt angesehene Inhalte in diesem Browser behalten. Dein Verlauf bleibt auf diesem Gerät und wird nicht an Harbor gesendet. Abgespielte Videos können auch passende Videoempfehlungen sortieren.

Bis zu 120 Einträge · 90 Tage. Ausschalten löscht den Verlauf.
Merkliste & Verlauf öffnen →

Über dieses Video

Creator-Beschreibung · OriginaltextTextsprache: Englisch (Vereinigte Staaten)

Subscribe to our channel: https://www.youtube.com/@mkaeberlein What if some of the most important drivers of Alzheimer's disease have nothing to do with amyloid plaques—and everything to do with aging biology? In this episode of Longevity Science, I sit down with Dr. Veronica Galvan, Director of the Nathan Shock Center at the University of Oklahoma and Editor-in-Chief of Geroscience, to explore more than a decade of groundbreaking research on mTOR, rapamycin, brain aging, and Alzheimer's disease. Dr. Galvan was among the first researchers to demonstrate that inhibiting mTOR with rapamycin can restore cognitive function, cerebral blood flow, neurovascular coupling, and blood-brain barrier integrity in animal models of Alzheimer's disease and age-related cognitive decline. Even more remarkably, many of these benefits were observed when treatment began after deficits had already developed. We discuss: 🔹 Why aging is the greatest risk factor for Alzheimer's disease 🔹 How mTOR contributes to brain aging and neurodegeneration 🔹 The surprising role of blood vessels in cognitive function 🔹 Rapamycin's effects on cerebral blood flow and the blood-brain barrier 🔹 Evidence for reversal of cognitive deficits in aging mice and rats 🔹 Why nitric oxide signaling may be important—but not sufficient 🔹 Tau pathology, cellular senescence, and inflammation in the aging brain 🔹 Whether senolytics or senomorphics are the better therapeutic strategy 🔹 The mystery of "resilient" individuals who maintain normal cognition despite significant Alzheimer's pathology 🔹 Why large, placebo-controlled human rapamycin trials are urgently needed This conversation dives deep into one of the most promising—and still underexplored—areas of aging biology. If you're interested in Alzheimer's disease, dementia prevention, rapamycin, or the biology of brain aging, this is an episode you won't want to miss. #Longevity #Alzheimers #Rapamycin #BrainHealth #Aging #Dementia #mTOR #Neuroscience #HealthyAging #Geroscience DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find me: Instagram: https://www.instagram.com/mkaeberlein/ LinkedIn: https://www.linkedin.com/in/mkaeberlein/ Twitter: https://twitter.com/mkaeberlein Facebook: https://www.facebook.com/matt.kaeberlein/ --- Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this channel I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Matt Kaeberlein · 60 min · Quelle veröffentlicht: 2026-06-17

Zu Harbor hinzugefügt: 23.10.2026

Original auf YouTube ↗

Automatisch eingeordnete Quelle. Creator-Aussagen sind keine unabhängige Evidenzprüfung und keine persönliche medizinische Beratung.

Diskussion

Community-Diskussionen

0 Themen

Mitgliederbeiträge. Quellen nennen, kommerzielle Interessen offenlegen und keine persönliche medizinische Beratung oder Dosierungsempfehlungen geben.

Wird geladen…